Additional Metadata
Persistent URL dx.doi.org/10.1007/s40273-018-0708-4, hdl.handle.net/1765/111392
Journal PharmacoEconomics
Citation
Büyükkaramikli, N.C, de Groot, S, Riemsma, R, Fayter, D., Armstrong, N, Portegijs, P., … Al, M.J. (2018). Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. doi:10.1007/s40273-018-0708-4